Skip to content

Current ratio at other companies

Merck & Co. logo
Merck & Co.MRK
1.3×-0.1×
Indivior Pharmaceuticals, Inc.
 logo
Indivior Pharmaceuticals, Inc. INDV
0.9×0.0×
LQD
Liquidia CorporationLQDA
2.2×-0.7×
United Therapeutics logo
United TherapeuticsUTHR
4.8×-0.7×

Other financials

Income statement

See full
Operating income-$14.9M-30.0%
Net income-$13.2M-27.6%
EPS (diluted)-$0.090.0%

Balance sheet

See full
Cash & equivalents$19.4M+0.2%
Total debt$682.0K-28.7%
Total equity$172.1M+73.1%
Total assets$179.6M+67.8%

Cash flow

See full
Operating cash flow-$16.7M-23.8%
CapEx$102.0K
Free cash flow-$16.8M

Valuation

See full
Market cap$2.47B+152%
Enterprise value$2.45B+157%

Returns & leverage

See full
Return on equity-33.6%-9.4pp
Debt / equity0.0×

Where this comes from

Calculated from Trevi Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Trevi Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Trevi Therapeutics, Inc.'s current ratio?
Trevi Therapeutics, Inc. (TRVI) reported current ratio of 24.8× in Q1 2026.
How has Trevi Therapeutics, Inc.'s current ratio changed year-over-year?
Trevi Therapeutics, Inc.'s current ratio increased by 60.9% year-over-year, from 15.4× to 24.8×.
What is the long-term trend for Trevi Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s current ratio has grown at a 18.7% compound annual growth rate (CAGR), from 8.3× to 19.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.